肝癌成纤维细胞激活蛋白显像:[68Ga]Ga-FAPI-04 PET/CT与MRI及[18F]-FDG PET/CT的单中心回顾性比较
本研究为单中心回顾性分析,纳入34例确诊或疑似肝脏病变患者,比较[68Ga]Ga-FAPI-04 PET/CT与CE-CT、肝脏MRI及[18F]-FDG PET/CT对原发及转移性肝癌的诊断效能。结果显示FAPI-04对原发肝肿瘤的敏感性与CE-CT和MRI相当,对肝内及恶性病灶的检出率显著高于FDG PET/CT。
要点
- FAPI-04对原发肝肿瘤敏感性96%,与CE-CT(96%)和MRI(100%)相当。
- FAPI-04对肝内病灶检出率85%,显著高于FDG PET/CT的52%(P<0.001)。
- FAPI-04对恶性病灶检出率87.4%,显著高于FDG PET/CT的65.0%(P<0.001)。
核心结论
- FAPI-04 PET/CT识别原发肝肿瘤和转移灶的敏感性相当于CE-CT和肝脏MRI。
- FAPI-04 PET/CT对肝内病灶的识别优于[18F]-FDG PET/CT,可能改善肿瘤分期、复发检测及治疗调整。
研究设计与样本
- 单中心事后回顾性分析,数据来自前瞻性母研究(NCT04416165)。
- 纳入34例确诊或疑似肝脏病变患者,均行[68Ga]Ga-FAPI-04和[18F]-FDG/CT扫描。
- 患者同时接受肝脏MRI(n=34)和CE-CT(n=25);最终诊断参考标准为组织病理学(n=62)或影像学随访(n=128)。
主要发现
- 34例患者中,肝细胞癌20例、肝内胆管癌12例、良性肝结节2例。
- CE-CT、MRI、[68Ga]Ga-FAPI-04和[18F]-FDG/CT检测原发肝肿瘤的敏感性分别为96%、100%、96%和65%。
- 所有肝内病灶的检出率:[68Ga]Ga-FAPI-04 PET/CT为85%,略低于MRI的100%(P=0.34),显著高于[18F]-FDG PET/CT的52%(P<0.001)。
- 所有恶性病灶(包括肝外病变)的肿瘤检出率:[68Ga]Ga-FAPI-04 PET/CT为87.4%,显著高于[18F]-FDG PET/CT的65.0%(P<0.001)。
关键数值与推荐
- 原发肝肿瘤敏感性:CE-CT 96%、MRI 100%、[68Ga]Ga-FAPI-04 96%、[18F]-FDG/CT 65%。
- 肝内病灶检出率:[68Ga]Ga-FAPI-04 85% vs. MRI 100%(P=0.34);[68Ga]Ga-FAPI-04 85% vs. [18F]-FDG 52%(P<0.001)。
- 恶性病灶检出率:[68Ga]Ga-FAPI-04 87.4% vs. [18F]-FDG 65.0%(P<0.001)。
临床怎么用
- 对于肝癌原发灶诊断,FAPI-04 PET/CT可达到与CE-CT和MRI相当的敏感性。
- 在需要排除肝内或肝外恶性病灶时,FAPI-04 PET/CT检出率显著优于FDG PET/CT。
- FAPI-04 PET/CT可能有助于肿瘤分期、复发检测及治疗决策调整。
局限性
- 单中心事后回顾性分析,样本量较小(34例)。
- CE-CT仅在25例患者中进行,并非所有患者均有对照。
- 参考标准部分依赖影像学随访而非全部组织病理学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate the potential utility of [68Ga]Ga-FAPI-04 PET/CT for diagnosing primary and metastatic lesions in patients with liver cancer, as well as to compare it with contrast-enhanced CT (CE-CT), liver MRI, and [18F]-FDG PET/CT. METHODS: We performed a single-center post hoc retrospective analysis of data obtained from a prospective parent study (NCT04416165). This study included 34 patients diagnosed with or suspected hepatic lesions who underwent concomitant [68Ga]Ga-FAPI-04 and [18F]-FDG/CT scans. Moreover, these patients underwent liver MRI (n = 34) and CE-CT (n = 25). Histopathologic (n = 62) or radiographic follow-up (n = 128) served as the reference standard for the final diagnosis. RESULTS: Among the 34 patients, 20, 12, and 2 patients presented with hepatocellular carcinomas, intrahepatic cholangiocarcinomas, and benign hepatic nodules, respectively. The sensitivities of CE-CT, MRI, [68Ga]Ga-FAPI-04, and [18F]-FDG/CT for detecting primary liver tumors were 96%, 100%, 96%, and 65%, respectively. Regarding the diagnosis of all intrahepatic lesions, the per-lesion detection rate of [68Ga]Ga-FAPI-04 PET/CT was slightly lower than that of MRI (85% vs. 100%, P = 0.34) and significantly higher than that of [18F]-FDG PET/CT (85% vs. 52%, P < 0.001). Regarding the diagnosis of all malignant lesions (including extrahepatic disease), the tumor detection rate of [68Ga]Ga-FAPI-04 PET/CT was 87.4%, which was significantly higher than that of [18F]-FDG PET/CT (65.0%, P < 0.001). CONCLUSIONS: Our findings indicate that the sensitivity of [68Ga]Ga-FAPI-04 PET/CT to correctly identify primary liver tumors and metastatic lesions is equivalent to that of CE-CT and liver MRI. Moreover, [68Ga]Ga-FAPI-04 PET/CT is better at identifying liver lesions than [18F]-FDG PET/CT, and its use may improve tumor staging, recurrence detection, and implementation of necessary treatment modifications.
引用
- Guo W, Pang Y, Yao L, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2020. PMID: 33179149. doi:10.1007/s00259-020-05095-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。